AGC Biologics and Rocket Pharma expand LVV manufacturing partnership
![](/46/pdcnewsitem/11/18/61/HLN00CPO%20AGC%20Biologics-Milan990x525.jpg)
AGC Biologic's Milan facility
The expanded agreement will ensure Rocket Pharma's supply of lentiviral vectors across its pipeline
Global biopharmaceutical contract development and manufacturing organisation (CDMO) AGC Biologics says it has expanded its partnership with Rocket Pharmaceuticals to manufacture lentiviral vectors for the company across its entire LVV pipeline.
AGC Biologics will manufacture LVVs at its Center of Excellence for Cell and Gene Therapy services in Milan, Italy, using the 48L Cell Factory Systems and iCellis 500 bioreactor platforms.
AGC Biologics said it has developed a reproducible, high quality and quantity process for the industrial-scale production of LVV in response to customer needs and market demand.
"This process allows for the successful scale of LVV manufacture without affecting critical quality attributes (CQA), ultimately improving the commercial viability of LVV-based gene therapies," the CDMO said.
In February, AGC Biologics announced the expansion of its Milan facility, which it had acquired in July 2020 after its takeover of Italian biotech MolMed, and which was the first GMP facility approved in Europe for ex vivo gene therapy manufacturing.
The company expects to complete the expansion in 2022.
![AGC Biologics](https://www.cphi-online.com/c272056th_S-comp272056.jpg)
Related News
-
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance